Charlotte
Teunissen
Dept. Clinical Chemistry, VU University Medical Center, Amsterdam,
Netherlands
Charlotte Teunissen’s drive is to improve care of patients with
neurological diseases by developing body fluid biomarkers for
diagnosis, stratification, prognosis and monitoring treatment
responses. Studies of her research group span the entire spectrum of
biomarker development, starting with biomarker identification, often
by –omics methods, followed by biomarker assay development and
analytical validation, and lastly, extensive clinical validation and
implementation of novel biomarkers in clinical practice.
She has extensive expertise with assay development on state of the
art technologies, such as mass spectrometry and antibody-based arrays
for biomarker discovery, ultrasensitive immunoassays, and in in
implementation of vitro diagnostic technologies for clinical routine
lab analysis. She is responsible for the large well-characterised
biobank of the Amsterdam Dementia cohort, containing >6000 paired
CSF and serum samples of individuals visiting the memory clinical of
the Alzheimer Center Amsterdam (a.o. controls, patients with
Alzheimer, Frontotemporal, Lewy Bodies).To ensure the quality of the
biosamples, the group studies pre-analytical effects, which are key
to implementation. Charlotte is leading several collaborative
international biomarkernetworks, such as the Society for
Neurochemistry and routine CSF analysis and the Alzheimer
Association-Global Biomarker Standardization and Blood Based
Biomarkers and the Body fluid Biomarkers PIA, , and the recently
founded Coral proteomics consortium. She is the coordinator of the
Marie Curie MIRIADE project, aiming to train 15 novel researchers into
innovative strategies to develop dementia biomarkers (10 academic
centers + 10 non-academic centers), and the JPND bPRIDE project, that
aims to develop targeted blood based biomarker panels for early
differential diagnoses of specific dementias and is a collaborative
project between 7 European and 1 Australian centers.